With the totality of clinical data consistently pointing to FOXA2 as a promising candidate, we focused on further exploring the potential role of FOXA2 as a promoter of metastatic competence in SCLC experimental model systems. The gene discussed is FOXA2; the disease is small cell lung carcinoma.